sharon sanders
Editor-in-Chief & President
Contraception and HIV infection in women.
Heikinheimo O, L?hteenm?ki P. Department of Obstetrics and Gynaecology, University of Helsinki, Finland. oskari.heikinheimo@helsinki.fi
BACKGROUND: More than 15 million women, many of reproductive age, were infected with human immunodeficiency virus (HIV) at the end of 2007. As the HIV epidemic evolves, heterosexual intercourse is increasingly risky: the risk of infection in exposed young women is 4- to 7-fold higher than in young men and nearly half a million newborns annually have HIV. This review aims to show the effect of contraceptive choices on risk of HIV and on the course of disease in women with HIV.
METHODS: Relevant citations were selected by agreement between the authors after a search of MEDLINE using the terms HIV/AIDS and contraception.
RESULTS: Risk of transmission of HIV varies from 1 in 200 to 1 in 10 000 coital incidents, depending in part on the integrity of the vaginal epithelium. Consistent use of male condoms has been proven to reduce horizontal transmission of HIV by 80% among HIV-serodiscordant couples. Hormonal contraception may increase the risk of HIV acquisition in high-risk women such as commercial sex workers, but not in women at low risk of HIV. While hormonal contraception did not affect progression of disease in two cohort studies involving 370 women, in a randomized trial among women not receiving antiretroviral medication, clinical disease accelerated in the oral contraception group (13.2/100 woman-years) compared with the copper intrauterine devices group (8.6/100 woman-years; hazard ratio, 1.5; 95% confidence interval, 1.04-2.1). Hormonal contraception does not interfere with antiviral drug effectiveness.
CONCLUSIONS: All the available reversible contraceptive methods can generally be used by women at risk of HIV infection and by HIV-infected women. Further studies are needed to investigate the safety and efficiency of hormonal contraception in women living with HIV/AIDS.
snip
Barrier methods are effective in reducing the risk of HIV transmission
<!-- null --> Male condoms
As of today, male condoms are the only means proven to significantly<sup> </sup>reduce the risk of HIV transmission in heterosexual intercourse<sup> </sup>(Cates, 2005
). According to a recent Cochrane review, consistent<sup> </sup>use of male condoms results in 80% reduction in the risk of<sup> </sup>HIV transmission among HIV-serodiscordant couples (Weller and<sup> </sup>Davis-Beaty, 2002
). Of the studies including only HIV-negative<sup> </sup>women and their HIV-infected men, the efficacy of consistent<sup> </sup>condom use in prevention of HIV transmission was remarkable,<sup> </sup>with a relative risk varying from 0.1 to 0.2 (Saracco et al.,<sup> </sup>1993
; Musicco et al., 1994
). Morover, during the follow-up period<sup> </sup>of nearly 2 years, De Vincenzi (1994)
<sup> </sup>among the 124 couples consistently using condoms. reported no seroconversions<sup> </sup>
It is also noteworthy that a reduced risk of HIV transmission<sup> </sup>is associated only with consistent but not with occasional condom<sup> </sup>use. In fact, occasional condom use has been associated with<sup> </sup>an increased risk of HIV transmission in some studies (Saracco<sup> </sup>et al., 1993
; Musicco et al., 1994
). However, a major challenge<sup> </sup>in evaluation of condom use is that the data is self-reported<sup> </sup>and therefore, in many cases, its reliability may be questionable.<sup> </sup>This is related especially to consistency of use.<sup> </sup>
Many of the studies involving assessment of the efficacy of<sup> </sup>male condoms in prevention of HIV transmission were carried<sup> </sup>out before the era of effective antiretroviral medication. The<sup> </sup>use of zidovudine monotherapy by the HIV-infected male partner<sup> </sup>has been reported to halve the risk of HIV transmission (Musicco<sup> </sup>et al., 1994
), and during the use of current combination therapy<sup> </sup>the rate of HIV transmission was even lower (Castilla et al.,<sup> </sup>2005
). No HIV transmissions were reported among serodiscordant<sup> </sup>couples if the HIV-infected partner received HAART and a condom<sup> </sup>was used every time the couple had sex (Castilla et al., 2005
).<sup> </sup>
Given the efficacy of consistent use of male condoms in the<sup> </sup>prevention of HIV transmission in heterosexual intercourse,<sup> </sup>it is disappointing to note the low prevalence of condom use<sup> </sup>reported in many studies. In addition, the rate of reported<sup> </sup>condom use varies greatly in studies performed in different<sup> </sup>continents. The lowest rate of condom use is reported in studies<sup> </sup>carried out in Africa. Only 10% or less of African women participating<sup> </sup>in studies involving assessment of the safety of hormonal contraception<sup> </sup>among women at risk of HIV (Tables III and IV) reported<sup> </sup>the dual use of hormonal contraception and condoms (Kiddugavu<sup> </sup>et al., 2003
; Morrison et al., 2007
; Myer et al., 2007
). Similarly,<sup> </sup>condom use at any time was reported by <10% of HIV-infected<sup> </sup>women participating in a study in which the use of a Cu-releasing<sup> </sup>intrauterine device (Cu-IUDs) was assessed (Richardson et al.,<sup> </sup>1999
).
http://humupd.oxfordjournals.org/cgi/content/full/15/2/165
Heikinheimo O, L?hteenm?ki P. Department of Obstetrics and Gynaecology, University of Helsinki, Finland. oskari.heikinheimo@helsinki.fi
BACKGROUND: More than 15 million women, many of reproductive age, were infected with human immunodeficiency virus (HIV) at the end of 2007. As the HIV epidemic evolves, heterosexual intercourse is increasingly risky: the risk of infection in exposed young women is 4- to 7-fold higher than in young men and nearly half a million newborns annually have HIV. This review aims to show the effect of contraceptive choices on risk of HIV and on the course of disease in women with HIV.
METHODS: Relevant citations were selected by agreement between the authors after a search of MEDLINE using the terms HIV/AIDS and contraception.
RESULTS: Risk of transmission of HIV varies from 1 in 200 to 1 in 10 000 coital incidents, depending in part on the integrity of the vaginal epithelium. Consistent use of male condoms has been proven to reduce horizontal transmission of HIV by 80% among HIV-serodiscordant couples. Hormonal contraception may increase the risk of HIV acquisition in high-risk women such as commercial sex workers, but not in women at low risk of HIV. While hormonal contraception did not affect progression of disease in two cohort studies involving 370 women, in a randomized trial among women not receiving antiretroviral medication, clinical disease accelerated in the oral contraception group (13.2/100 woman-years) compared with the copper intrauterine devices group (8.6/100 woman-years; hazard ratio, 1.5; 95% confidence interval, 1.04-2.1). Hormonal contraception does not interfere with antiviral drug effectiveness.
CONCLUSIONS: All the available reversible contraceptive methods can generally be used by women at risk of HIV infection and by HIV-infected women. Further studies are needed to investigate the safety and efficiency of hormonal contraception in women living with HIV/AIDS.
snip
Barrier methods are effective in reducing the risk of HIV transmission
<!-- null --> Male condoms
As of today, male condoms are the only means proven to significantly<sup> </sup>reduce the risk of HIV transmission in heterosexual intercourse<sup> </sup>(Cates, 2005
It is also noteworthy that a reduced risk of HIV transmission<sup> </sup>is associated only with consistent but not with occasional condom<sup> </sup>use. In fact, occasional condom use has been associated with<sup> </sup>an increased risk of HIV transmission in some studies (Saracco<sup> </sup>et al., 1993
Many of the studies involving assessment of the efficacy of<sup> </sup>male condoms in prevention of HIV transmission were carried<sup> </sup>out before the era of effective antiretroviral medication. The<sup> </sup>use of zidovudine monotherapy by the HIV-infected male partner<sup> </sup>has been reported to halve the risk of HIV transmission (Musicco<sup> </sup>et al., 1994
Given the efficacy of consistent use of male condoms in the<sup> </sup>prevention of HIV transmission in heterosexual intercourse,<sup> </sup>it is disappointing to note the low prevalence of condom use<sup> </sup>reported in many studies. In addition, the rate of reported<sup> </sup>condom use varies greatly in studies performed in different<sup> </sup>continents. The lowest rate of condom use is reported in studies<sup> </sup>carried out in Africa. Only 10% or less of African women participating<sup> </sup>in studies involving assessment of the safety of hormonal contraception<sup> </sup>among women at risk of HIV (Tables III and IV) reported<sup> </sup>the dual use of hormonal contraception and condoms (Kiddugavu<sup> </sup>et al., 2003
http://humupd.oxfordjournals.org/cgi/content/full/15/2/165
